1

SEQUENCE LISTING

<110> GEORGES, ELIAS <120> HSC70 DIRECTED DIAGNOSTICS AND THERAPEUTICS FOR MULTIDRUG RESISTANT NEOPLASTIC DISEASE <130> 112418.149US (AUR-011US) <140> 10/737,350 <141> 2003-12-15 <150> 60/438,012 <151> 2003-01-03 <160> 27 <170> PatentIn Ver. 3.2 <210> 1 <211> 646 <212> PRT <213> Homo sapiens <400> 1 Met Ser Lys Gly Pro Ala Val Gly Ile Asp Leu Gly Thr Thr Tyr Ser 1 5 10 15 Cys Val Gly Val Phe Gln His Gly Lys Val Glu Ile Ile Ala Asn Asp 20 25 30 Gln Gly Asn Arg Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu 35 40 45 Arg Leu Ile Gly Asp Ala Ala Lys Asn Gln Val Ala Met Asn Pro Thr 50 55 60 Asn Thr Val Phe Asp Ala Lys Arg Leu Ile Gly Arg Arg Phe Asp Asp 65 70 75 80 Ala Val Val Gln Ser Asp Met Lys His Trp Pro Phe Met Val Val Asn 85 90 95 Asp Ala Gly Arg Pro Lys Val Gln Val Glu Tyr Lys Gly Glu Thr Lys 100 105 110 Ser Phe Tyr Pro Glu Glu Val Ser Ser Met Val Leu Thr Lys Met Lys 115 120 125 Glu Ile Ala Glu Ala Tyr Leu Gly Lys Thr Val Thr Asn Ala Val Val 130 135 140 Thr Val Pro Ala Tyr Phe Asn Asp Ser Gln Arg Gln Ala Thr Lys Asp 145 150 155 160 Ala Gly Thr Ile Ala Gly Leu Asn Val Leu Arg Ile Ile Asn Glu Pro 165 170 175

Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Lys Lys Val Gly Ala Glu Arg Asn Val Leu Ile Phe Asp Leu Gly Gly Gly Thr Phe Asp Val Ser Ile Leu Thr Ile Glu Asp Gly Ile Phe Glu Val Lys Ser Thr Ala Gly Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg Met Val Asn His Phe Ile Ala Glu Phe Lys Arg Lys His Lys Lys Asp Ile Ser Glu Asn Lys Arg Ala Val Arg Arg Leu Arg Thr Ala Cys Glu Arg Ala Lys Arg Thr Leu Ser Ser Ser Thr Gln Ala Ser Ile Glu Ile Asp Ser Leu Tyr Glu Gly Ile Asp Phe Tyr Thr Ser Ile Thr Arg Ala Arg Phe Glu Glu Leu Asn Ala Asp Leu Phe Arg Gly Thr Leu Asp Pro Val Glu Lys Ala Leu Arg Asp Ala Lys Leu Asp Lys Ser Gln Ile His Asp Ile Val Leu Val Gly Gly Ser Thr Arg Ile Pro Lys Ile Gln Lys Leu Leu Gln Asp Phe Phe Asn Gly Lys Glu Leu Asn Lys Ser Ile Asn Pro Asp Glu Ala Val Ala Tyr Gly Ala Ala Val Gln Ala Ala Ile Leu Ser Gly Asp Lys Ser Glu Asn Val Gln Asp Leu Leu Leu Asp Val Thr Pro Leu Ser Leu Gly Ile Glu Thr Ala Gly Gly Val Met Thr Val Leu Ile Lys Arg Asn Thr Thr Ile Pro Thr Lys Gln Thr Gln Thr Phe Thr Thr Tyr Ser Asp Asn Gln Pro Gly Val Leu Ile Gln Val Tyr Glu Gly Glu Arg Ala Met Thr Lys Asp Asn Asn Leu Leu Gly Lys Phe Glu Leu Thr Gly Ile Pro Pro Ala Pro Arg Gly Val Pro Gln Ile Glu Val Thr Phe Asp Ile

Asp Ala Asn Gly Ile Leu Asn Val Ser Ala Val Asp Lys Ser Thr Gly 485 490 495 Lys Glu Asn Lys Ile Thr Ile Thr Asn Asp Lys Gly Arg Leu Ser Lys 500 505 510 Glu Asp Ile Glu Arg Met Val Gln Glu Ala Glu Lys Tyr Lys Ala Glu 515 520 525 Asp Glu Lys Gln Arg Asp Lys Val Ser Ser Lys Asn Ser Leu Glu Ser 530 535 540 Tyr Ala Phe Asn Met Lys Ala Thr Val Glu Asp Glu Lys Leu Gln Gly 545 550 555 560 Lys Ile Asn Asp Glu Asp Lys Gln Lys Ile Leu Asp Lys Cys Asn Glu 565 575 570 Ile Ile Asn Trp Leu Asp Lys Asn Gln Thr Ala Glu Lys Glu Glu Phe 580 585 590 Glu His Gln Gln Lys Glu Leu Glu Lys Val Cys Asn Pro Ile Ile Thr 595 600 605 Lys Leu Tyr Gln Ser Ala Gly Gly Met Pro Gly Gly Met Pro Gly Gly 610 615 620 Phe Pro Gly Gly Gly Ala Pro Pro Ser Gly Gly Ala Ser Ser Gly Pro 625 630 635 640 Thr Ile Glu Glu Val Asp 645 <210> 2 <211> 1941 <212> DNA <213> Homo sapiens <400> 2 atgtccaagg gacctgcagt tggtattgat cttggcacca cctactcttg tgtgggtgtt 60 ttccagcacg gaaaagtcga gataattgcc aatgatcagg gaaaccgaac cactccaagc 120 tatgtcgcct ttacggacac tgaacggttg atcggtgatg ccgcaaagaa tcaagttgca 180 atgaacccca ccaacacagt ttttgatgcc aaacgtctga ttggacgcag atttgatgat 240 gctgttgtcc agtctgatat gaaacattgg ccctttatgg tggtgaatga tgctgqcagg 300 cccaaggtcc aagtagaata caagggagag accaaaagct tctatccaga ggaggtgtct 360 tctatggtte tgacaaagat gaaggaaatt gcagaageet acettgggaa gaetgttace 420 aatgetgtgg teacagtgee agettaettt aatgaetete agegteagge taecaaagat 480 gctggaacta ttgctggtct caatgtactt agaattatta atgagccaac tgctgctgct 540 attgettacg gettagacaa aaaggttgga geagaaagaa aegtgeteat etttgaeetg 600 ggaggtggca cttttgatgt gtcaateete actattgagg atggaatett tgaggteaag 660 tctacagctg gagacaccca cttgggtgga gaagattttg acaaccgaat ggtcaaccat 720 tttattgctg agtttaagcg caagcataag aaggacatca gtgagaacaa gagagctgta 780 agacgeetee gtactgettg tgaacgtget aagegtaeee tetetteeag caeceaggee 840 agtattgaga tegattetet etatgaagga ategaettet ataceteeat taecegtgee 900 cgatttgaag aactgaatgc tgacctgttc cgtggcaccc tggacccagt agagaaagcc 960 cttcgagatg ccaaactaga caagtcacag attcatgata ttgtcctggt tggtggttct 1020 actogtatee ceaagattea gaagettete caagaettet teaatggaaa agaactgaat 1080

aagagcatca accetgatga agetgttget tatggtgeag etgteeagge agecatettg 1140 tctggagaca agtctgagaa tgttcaagat ttgctgctct tggatgtcac tcctctttcc 1200 cttggtattg aaactgctgg tggagtcatg actgtcctca tcaagcgtaa taccaccatt 1260 cctaccaagc agacacagac cttcactacc tattctgaca accagectgg tgtgcttatt 1320 caggtttatg aaggcgagcg tgccatgaca aaggataaca acctgcttgg caagtttgaa 1380 ctcacaggca tacctcctgc accccgaggt gttcctcaga ttgaagtcac ttttgacatt 1440 gatgccaatg gtatactcaa tgtctctgct gtggacaaga gtacgggaaa agagaacaag 1500 attactatca ctaatgacaa gggccgtttg agcaaggaag acattgaacg tatggtccag 1560 gaagctgaga agtacaaagc tgaagatgag aagcagaggg acaaggtgtc atccaagaat 1620 tcacttgagt cctatgcctt caacatgaaa gcaactgttg aagatgagaa acttcaaggc 1680 aagattaacg atgaggacaa acagaagatt ctggacaagt gtaatgaaat tatcaactgg 1740 cttgataaga atcagactgc tgagaaggaa gaatttgaac atcaacagaa agagctggag 1800 aaagtttgca accccatcat caccaagctg taccagagtg caggaggcat gccaggagga 1860 atgeetgggg gattteetgg tggtggaget ceteettetg gtggtgette eteagggeee 1920 accattgaag aggttgatta a 1941 <210> 3 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 3 Met Val Asn His Phe Ile Ala Glu Phe Lys 1 5 10 <210> 4 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400>4Phe Glu Glu Leu Asn Ala Asp Leu Phe Arg 1 5 10 <210> 5 <211> 11 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 5 Met Val Asn His Phe Ile Ala Glu Phe Lys Arg 10 1 5

<210> 6 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 6 Ala Arg Phe Glu Glu Leu Asn Ala Asp Leu Phe Arg 1 5 10 <210> 7 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 7 Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu Arg 1 5 10 <210> 8 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 8 Ser Thr Ala Gly Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg 1 5 10 15 <210> 9 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 9 Ile Ile Asn Glu Pro Thr Ala Ala Ala Ile Ala Tyr Gly Leu Asp Lys 1 5 10 15

Ð

Lys

<210> 10 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 10 Asn Gln Val Ala Met Asn Pro Thr Asn Thr Val Phe Asp Ala Lys Arg 1 5 10 15 <210> 11 <211> 17 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 11 Leu Asp Lys Ser Gln Ile His Asp Ile Val Leu Val Gly Gly Ser Thr 1 5 10 15 Arg <210> 12 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 12 Asp Asn Asn Leu Leu Gly Lys Phe Glu Leu Thr Gly Ile Pro Pro Ala 1 5 10 15 Pro Arg <210> 13 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide

<400> 13 Thr Val Thr Asn Ala Val Val Thr Val Pro Ala Tyr Phe Asn Asp Ser 1 5 10 15 Gln Arg <210> 14 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 14 Gln Thr Gln Thr Phe Thr Thr Tyr Ser Asp Asn Gln Pro Gly Val Leu 1 5 10 15 Ile Gln Val Tyr Glu Gly Glu Arg 20 <210> 15 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 15 Asp Ala Gly Thr Ile Ala Gly Leu Asn Val Leu Arg 1 5 10 <210> 16 <211> 10 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 16 Phe Glu Glu Leu Asn Ala Asp Leu Phe Arg 1 5 10 <210> 17 <211> 11 <212> PRT <213> Artificial Sequence

<220> <223> Description of Artificial Sequence: Synthetic peptide <400> 17 Met Val Asn Arg Phe Ile Ala Glu Phe Lys Arg 5 1 10 <210> 18 <211> 12 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 18 Ala Arg Phe Glu Glu Ile Asn Ala Asp Leu Phe Arg 1 5 10 <210> 19 <211> 13 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 19 Thr Thr Pro Ser Tyr Val Ala Phe Thr Asp Thr Glu Arg 1 5 10 <210> 20 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 20 Ser Thr Ala Gly Asp Thr His Leu Gly Gly Glu Asp Phe Asp Asn Arg 1 5 10 15 <210> 21 <211> 17 <212> PRT <213> Artificial Sequence

<220> <223> Description of Artificial Sequence: Synthetic peptide <400> 21 Leu Asp Lys Ser Gln Thr His Asp Ile Val Leu Val Gly Gly Ser Thr 1 5 10 15 Arg <210> 22 <211> 14 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 22 Gly Thr Leu Asp Pro Val Glu Lys Ala Leu Arg Asp Ala Lys 5 1 10 <210> 23 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 23 Thr Val Thr Asn Ala Val Val Thr Val Pro Ala Tyr Phe Asn Asp Ser 1 5 10 15 Gln Arg <210> 24 <211> 16 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 24 Met Val Gln Phe Ala Glu Lys Tyr Lys Ala Glu Asp Glu Lys Gln Arg 1 5 10 15 <210> 25 <211> 17 <212> PRT

<213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 25 Asn Gln Val Ala Ala Met Asn Pro Thr Asn Thr Val Phe Asp Ala Lys 1 5 10 15 Arg <210> 26 <211> 24 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 26 Gln Thr Gln Thr Phe Thr Thr Tyr Ser Asp Asn Gln Pro Gly Val Leu 1 5 10 15 Ile Gln Val Tyr Glu Gly Glu Arg 20 <210> 27 <211> 18 <212> PRT <213> Artificial Sequence <220> <223> Description of Artificial Sequence: Synthetic peptide <400> 27 Asn Ser Leu Glu Ser Tyr Ala Phe Asn Met Lys Ala Thr Val Glu Asp 1 5 10 15

Glu Lys

,